top of page

Search Results

Results found for "pain modeling"

  • 📰 GPCR Weekly News, February 27 to March 5, 2023

    Establishment of a CaCC-based Cell Model and Method for High-throughput Screening of M3 Receptor Drugs FSHR activation through small molecule modulators: Mechanistic insights from MD simulations. Structural and Molecular Insights into GPCR Function The activation mechanism and antibody binding mode has a new website Confo Therapeutics Announces Global Licensing Agreement with Lilly for Peripheral Pain

  • Assay Sensitivity: The Hidden Lever Driving GPCR Drug Discovery

    In this course, you’ll gain: ✅ How assay volume control  alters receptor sensitivity and what that By modulating receptor expression or sensitivity, we can shift the “lens” through which drug activity Model patient-like pathophysiological states (e.g., reduced receptor expression in heart failure). Adjusting assay sensitivity—whether through expression systems, chemical modulation, or engineered desensitization—provides landscape is dynamic—ligands compete, cooperate, and reshape receptor ensembles in ways that standard models

  • Target Residence Time: The Hidden Driver of In Vivo Efficacy

    From restricted tissue diffusion to PK–PD dissociation, Kenakin equips you with the kinetic models and In This Session, You’ll Gain: ✅ Modeling tools to understand how restricted diffusion  in tissues like Residence time provides a second dimension of drug evaluation , one that explains results in animal models Kenakin offers not just theory, but tools to model, predict, and validate this behavior early.

  • How Schild Analysis Protects Your Conclusions in GPCR Research

    Breakthroughs this week: McGPCR multimodal model; Endocrine Metabolic GPCRs 2026; Pfizer–Metsera acquisition why misclassification propagates error across affinity estimates, mechanism claims, and downstream modeling Watch the trailer 👇 What you’ll gain Validate the model behind the data.   You also gain access to member-only discounts, full GPCR University content, and an integrated view of

  • Exploring pharmacological inhibition of G q/11 as an analgesic strategy

    has pro-nociceptive properties, suggesting that blockade of Gq/11 signalling could be beneficial for pain Experimental approach: We used a series of behavioural assays to evaluate the acute responses of mice to painful

  • Opioid Receptors and Protonation-Coupled Binding of Opioid Drugs

    receptors are G-protein-coupled receptors (GPCRs) part of cell signaling paths of direct interest to treat pain Pain may associate with inflamed tissue characterized by acidic pH. The potentially low pH at tissue targeted by opioid drugs in pain management could impact drug binding

  • 📰 GPCR Weekly News, March 27 to April 4, 2023

    Negative allosteric modulation of the glucagon receptor by RAMP2. Regulator of G-Protein Signalling 4 (RGS4) negatively modulates nociceptin/orphanin FQ opioid receptor Therapeutic potential of opioid receptor heteromers in chronic pain and associated comorbidities. Investigating the potential of GalR2 as a drug target for neuropathic pain. The impact of cryo-EM on determining allosteric modulator-bound structures of G protein-coupled receptors

  • APEX2/AUR Biosensor: A Powerful Tool for Protein Interaction and Trafficking

    trafficking of DOR, facilitating its downregulation and influencing cellular signaling pathways essential for pain As the opioid crisis continues to challenge public health, insights gained from this research could inform

  • Unlocking the Future of Medicine: Advancements in GPCR Research

    3 activation Michael Trogdon, J Silvio Gutkind, Edward C Stites, et al., for their study on Systems modeling It is an opportunity to connect with like-minded scientists and researchers and gain valuable insights beige adipocyte formation: Implications for obesity and metabolic health GPCRs in Neuroscience Chronic modulation regulates energy homeostasis in response to pathogen infection GPCRs in Oncology and Immunology Systems modeling treatment based on drug repurposing demonstrates mutation-agnostic efficacy in pre-clinical retinopathy models

  • New role of β-arrestins in MOR signaling

    Opioids are analgesic drugs consumed non-medically for euphoric feelings and medically for pain relief most important in regulating the response to nociception, i.e. the response of the nervous system to painful Given their pathophysiological significance in pain, addiction and depression opioid receptors represent Morphine is one of the most widely used and proven analgesic for the treatment of severe acute or chronic pain Complex Persistent Opioid Dependence-an Opioid-induced Chronic Pain Syndrome.

  • Unlocking the Therapeutic Potential of Previously Undruggable GPCRs

    Orion’s receptor antagonist analogs have demonstrated powerful efficacies across a range of animal models In an ex vivo human endothelial transmigration model, OB-004 demonstrated an unprecedented level of monocyte In this model, OB-004 showed powerful efficacy, achieving full blockade of monocyte recruitment in response In vivo efficacy of murinized OB-004 (mOB-004) in the thioglycolate (TG) induced peritonitis murine model Demonstration of the in vivo efficacy of a systemically administered antagonist analog in a model

  • Purpose-Driven Opioid Research: Catherine Demery’s Academic Path

    Like many young scientists, she explored different paths and gained industry experience before realizing she collaborates with harm-reduction groups such as the Red Project in Grand Rapids  to ground her models This approach makes her models not just rigorous, but translational—bridging the gap between receptor Her next steps include using floxed mouse models  and viral tools  to dissect the downstream pathways Real-world data should guide how we build preclinical models.

  • GPCR Allostery: Unlock Hidden Mechanisms and Make Smarter Drug Decisions

    Welcome back GPCR fans, If your drug discovery strategy still relies on static GPCR models, you’re already Leverage this model to stay ahead of therapeutic complexity. It’s the 20th anniversary—and the spotlight is squarely on kinetic modeling, allosteric frameworks, and Access peer insights on allosteric modulators and biased ligands.

  • AlphaFold’s Breakthrough in GPCR Research: Revolutionizing Discovery, Yet Awaiting Experimental Proof

    Before the advent of AlphaFold, homology modeling was the most common method for predicting G protein-coupled Homology modeling relies on using the known structure of a homologous protein as a template to model For proteins with low sequence similarity to available templates, homology models tend to be less accurate targeting TAAR1, more than double that of the homology models. Ligand discovery from a dopamine D3 receptor homology model and crystal structure.

  • Artificial intelligence – faster, smarter, cheaper GPCR drug discovery

    ML algorithms typically use traditional ML models, such as decision trees and support vector machines While classical ML models are effective for datasets for which the relevant features are well understood which comprise handcrafted features and simpler models. For this reason, DL models generally require more computational resources (such as powerful GPUs) and Classification: AI models can be used to distinguish GPCRs from non-GPCRs, and to classify GPCRs into

  • GRK2 in cardiovascular disease and its potential as a therapeutic target

    Additionally, GPCR dysregulation underlies multiple models of cardiac pathology, and most pharmacological Current literature strongly establishes increased levels and activity of GRK2 in multiple models of CVD the GRK2 interactome includes numerous proteins which interact with differential domains of GRK2 to modulate the ongoing and future research for targeting this critical kinase across cellular, animal and human models

  • 📰 GPCR Weekly News, October 30 to November 4, 2023

    inhibits purinergic P2Y2 receptor and TRPV4 to suppress astrocyte activation and to relieve neuropathic pain GPCRs in Oncology and Immunology Systems Pharmacodynamic Model of Combination Gemcitabine and Trabectedin natural products for specific, testosterone-like, OXER1 antagonists A 19F-qNMR-Guided Mathematical Model

  • Drug Discovery Picks Up the Pace, Stays on Target

    They include small molecules that conditionally modulate proteins in their functional state; three-dimensional (3D) cell models, or organoid models, that assist with target identification, high-throughput drug screening

  • 🎄 Have Yourself a Merry Little GPCRmas! ❄ Dec 9 - 15, 2024

    of the proton-sensing GPCR, GPR65 on fibroblast-like synoviocytes contributes to inflammatory joint pain of the proton-sensing GPCR, GPR65 on fibroblast-like synoviocytes contributes to inflammatory joint pain

  • 📰 GPCR Weekly News, July 31 to August 6, 2023

    GPCR Symposium on 'GPCRs as Therapeutic Modalities' is set for September 22nd. Neuroscience Quinpirole ameliorates nigral dopaminergic neuron damage in Parkinson's disease mouse model diseases Ultrasensitive dose-response for asbestos cancer risk implied by new inflammation-mutation model the GPCR Smoothened and to the germline inducer Oskar Industry News Addex GABAb Positive Allosteric Modulator

  • GPCR Drug Discovery at Discovery on Target: Why This Track Is About More Than Receptors

    Dopamine D2 receptor modulators  – transforming treatment for Parkinson’s & schizophrenia. Allosteric modulation  for unprecedented precision. Serotonin & dopamine receptor modulation  for neuropsychiatric disorders. These sessions bridge structural biology , computational modeling , and clinical translation  — with

  • Exploring the Breakthroughs in GPCR Research

    research on the Relevance of GPCR dynamics for receptor activation, signalling bias and allosteric modulation G protein-coupled receptor (GPCR) dynamics for receptor activation, signalling bias and allosteric modulation Comprehensive Conformational Rearrangements of a G Protein-Coupled Receptor Influence of the Water Model Interactions of the GPR40 Protein with the Lipid Membrane and the Solvent: Rigid versus Flexible Water Models

  • The Perils and Guardrails of Modifying Signalling Proteins in Bioassays

    This limited detection and modelling of 5-HT2AR-Gαi/o coupling could mistakenly divert attention from and Gαi1, respectively (Figure 2B), as well as different coupling preferences between specific Gβγ pairs Allosteric modulation of G protein-coupled receptor signaling. Endogenous allosteric modulators of G protein-coupled receptors. delta opioid receptors is an endogenous mechanism and therapeutic target for relief from inflammatory pain

  • How to Use Statistical Methods to Strengthen Every GPCR Drug Discovery Decision

    Must-read publications:  A structural modeling study revealing non-canonical mechanisms of chemokine-driven From t-test, ANOVA, F-test selection to power analysis  that prevents underpowered studies, this module Gain career inspiration from Ajay’s bold questions and pivots.

  • Breaking the Myth of High and Low Affinity Sites

    In this session, you’ll gain:   ✅ A framework for understanding when apparent multiple affinities really Are You Using Models That Slow You Down?   Join Now — Access Immediate, Actionable Insight   You’ll gain the insight needed to:   Interpret complex

  • 📢 Early Bird Registration Ends Tomorrow! | Sep 16 - 22, 2024

    Gain access to over 500 minutes of recorded classes in our  GPCR courses   taught by Drs. signalling profiles GPCRs in Cardiology, Endocrinology, and Taste Cyclic adenosine monophosphate critically modulates of fingolimod (FTY720) and desensitization of S1P1 receptor-mediated G-protein activation in a mouse model Methods & Updates in GPCR Research GPCRSPACE: A New GPCR Real Expanded Library Based on Large Language Models

  • Community guidelines for GPCR ligand bias: IUPHAR review 32

    August 2022 "GPCRs modulate a plethora of physiological processes and mediate the effects of one-third requires that we now characterize physiological signalling not just by receptors but by ligand-receptor pairs implementation of the guidelines, together improving translation from in vitro to disease-relevant in vivo models

  • Identification of hub genes in the subacute spinal cord injury in rats

    The models of the three gene expression profiles were all for SCI to the thoracic segment of the rat. Module analysis was performed using Cytoscape.

  • Do You Believe AI Could Accelerate Drug Discovery?

    Lyu et al. prospectively docked ultra-large libraries of molecules against unrefined AF2 models of the They found that AF2 models achieved accurate side-chain predictions and successfully docked high-affinity Docking 490 million molecules against the σ2 receptor's AF2 model yielded a 54% hit rate, comparable Moreover, advanced AI models like AlphaFold3, which can predict complex protein-molecule interactions This proprietary nature limits direct access to the model and imposes a cap on daily predictions.

  • 🤯Mind-blowing GPCR Scoops! Discover the Latest Breakthroughs! ⦿ Nov 18 - 24, 2024

    Alexander S Hauser GPCRdb in 2025: adding odorant receptors, data mapper, structure similarity search and models anti-inflammatory drug binds at two distinct sites of a human bitter taste GPCR Photo-BQCA: Positive Allosteric Modulators Enabling Optical Control of the M1 Receptor The cell adhesion molecule CD44 acts as a modulator of 5 pharmacogenomics research GPCRdb in 2025: adding odorant receptors, data mapper, structure similarity search and models

bottom of page